Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

is open and Janssen plans to enroll 110 patients worldwide.
  • Phase Ib/II dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive non-Hodgkin's lymphoma. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP, once a safe dose is established the study will expand and report responses of this combination in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, is open and Janssen plans to enroll 33 patients.
  • Phase II study of ibrutinib in subjects with relapsed or refractory multiple myeloma (MM): This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in subjects with relapsed or relapsed MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. The Company anticipates an update on this study will be provided by year end 2013.
  • Phase II open-label, multicenter, single-arm study of monotherapy ibrutinib in subjects with relapsed or refractory follicular lymphoma. The primary endpoint of this study is objective response rate. Janssen plans to enroll 110 patients in this study.
  • PCYC has received Orphan Drug and Fast Track designation for ibrutinib treatment of chronic lymphocytic leukemia last year. The FDA has also granted Orphan Drug and Fast Track designation most recently to ibrutinib for the treatment of mantle cell lymphoma.  A US orphan drug designation provides the drug developer with several benefits and incentives related to the orphan drug, including a 7-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication. Fast tra
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/3/2015)... LEXINGTON, Ky. (PRWEB) March 03, 2015 ... aligning their schedules for one event: the Alltech REBELation ... USA, from May 17-20. Now in its 31st year, ... people from 70 countries, and the opportunity to join ... week, March 7 at 11:59 p.m. EST, at which ...
    (Date:3/3/2015)... 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life sciences ... products for advanced microarray diagnostics, today announced it ... its Management team. In his capacity as CFO ... from a development stage to a commercially successful ... Company,s capital market strategy and to secure funding ...
    (Date:3/3/2015)... FALLS, N.J. , March 3, 2015  Regenicin, ... biotechnology company specializing in the development of and commercialization ... damaged tissues and organs, announced today that it has ... Agreement with Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... under the Agreement, Amarantus made the final payments due ...
    (Date:3/3/2015)... 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... journal, Expert Opinion on Biological Therapy , Dr. ... Zhenggang Zhang , at the Henry Ford Hospital in ... beta 4 (TB4) has the capacity to promote CNS ... more post-injury, leading to neurological recovery in each case.  ...
    Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
    ... II still video system to directly acquire,images from ... Moores ,Stratagene , The Eagle Eye ... direct,imaging of chemiluminescent Western blots. The light-tight cabinet ... capture chemiluminescent signals. Also,the systems charge-coupled device (CCD) ...
    ... BlueNeurons are ideal for use in transplantation studies ... at High,Levels , , Michael McGrogan * Guadalupe ... California , , Stratagene's hNT BlueNeurons express beta-galactosidase ... of the NT2 teratocarcinoma stably transfected with a,lacZ ...
    ... PCR system, developed for,highfidelity PCR , , Kirk ... Daniel McMullan,* Barbara McGowan * Holly Hogrefe ,Stratagene Cloning ... the TaqPlus Precision PCR system,* to an expanding line ... a novel mixture of Taq2000 and Pfu DNA polymerases ...
    Cached Biology Technology:Imaging Chemiluminescent Western Blots 2Imaging Chemiluminescent Western Blots 3hNT BlueNeurons Express b-Galactosidase at High ,Levels 2hNT BlueNeurons Express b-Galactosidase at High ,Levels 3hNT BlueNeurons Express b-Galactosidase at High ,Levels 4hNT BlueNeurons Express b-Galactosidase at High ,Levels 5High-Fidelity PCR with a Novel Polymerase Mixture 2High-Fidelity PCR with a Novel Polymerase Mixture 3High-Fidelity PCR with a Novel Polymerase Mixture 4High-Fidelity PCR with a Novel Polymerase Mixture 5High-Fidelity PCR with a Novel Polymerase Mixture 6High-Fidelity PCR with a Novel Polymerase Mixture 7High-Fidelity PCR with a Novel Polymerase Mixture 8High-Fidelity PCR with a Novel Polymerase Mixture 9High-Fidelity PCR with a Novel Polymerase Mixture 10High-Fidelity PCR with a Novel Polymerase Mixture 11
    (Date:2/25/2015)... , Feb. 25, 2015  ABC Financial ... billing in the Health and Fitness Industry, today ... as to MYiCLUBonline.  The latest upgrade includes advances ... inclusion of cardless check-in via Identity One fingerprint ... first time through interactive displays at the International ...
    (Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
    (Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
    Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
    ... sub-Saharan Africa, according to the World Health Organization, and ... achieved limited success. But what if a vaccine against ... of Africa ?chancroid ?was relatively easy to develop and ... , That may be the case, according to researchers ...
    ... cells' own ability to correct themselves, will be outlined today ... European Society of Human Genetics in Amsterdam, The Netherlands. ... (commonly referred to as gene therapy) these new 'smart' approaches ... human biology. , Professor Brunhilde Wirth, from the Institute of ...
    ... technical advance in laboratory techniques may provide biology researchers ... the activity of targeted genes. RNA interference has recently ... function in normal biological processes and in disease. , ... on March 24, a research team from The Children's ...
    Cached Biology News:Vaccine shown effective against chancroid 2Vaccine shown effective against chancroid 3'Smart' genetic therapy helps the body to heal itself 2'Smart' genetic therapy helps the body to heal itself 3'Smart' genetic therapy helps the body to heal itself 4Interfering RNA silences genes in 'slippery' immune cells 2Interfering RNA silences genes in 'slippery' immune cells 3
    GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
    GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
    Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
    nuclear RNA export factor 1, mRNA...
    Biology Products: